Idexx Laboratories Inc (IDXX)
Health Care · Health Care Equipment · US stock · S&P 500 component
$560.36
▲ +13.18 (2.41%)
Fair valueOvervalued
$429 −23.4% to fair value
$215fair band $301–$558$644
Day's range
$552.62 – $566.55
52-week range
$500.61 – $769.98
About Idexx Laboratories Inc
Idexx Laboratories makes diagnostic tests and software for veterinarians, as well as testing products for water and livestock. It sells in-clinic analyzers and recurring consumables, runs a network of reference laboratories and provides practice management software. Revenue comes mostly from repeat purchases of tests and lab services, so it follows the number of veterinary visits and diagnostic testing.
Revenue at Idexx Laboratories Inc was $4.6 billion across the last twelve months. Across three years, sales expanded by 8.5% a year. Operating profit was 32.0% of revenue. It earned a return on invested capital of 59%. Debt after cash comes to 0.2 times EBITDA. There is no dividend. On the site's X-Ray Score, it rates 66 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $500.61 – $769.98Volume 708,800Daily, split-adjusted
Vitals
Market cap$44.4B
52-week range$500.61 – $769.98
Volume (last day)708,800
P/E (TTM)39.5
EBIT / EV yield3.3%
Free-cash-flow yield2.8%
Dividend yieldNo dividend
Revenue (TTM)$4.6B
Net income (TTM)$1.1B
Operating margin32.0%
Return on capital58.6%
Debt incl. leases$577M
Cash & securities$197M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$429model spread $403 – $456
Overvalued
−23.4% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $560
Undervalued < $301Fair $301 – $558Overvalued > $558
10-year DCF (market-scaled)
$526
Peer multiples
$389
Earnings power floor (not blended)
$150
Fundamentals-adjusted multiple
$373
Growth the price implies
19.7%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Healthy business, but priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
33/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.3%
Free-cash-flow yield2.8%
Fair value vs price0.8×
Growth
Strong
74/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)8.5%
EPS growth (3y)17.7%
Growth consistency100%
Profitability
Strong
86/100
Earns high returns on the capital it uses.
See the numbers →
Return on invested capital58.6%
Operating margin32.0%
Gross profitability82.6%
Financial health
Strong
78/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA0.2×
Interest cover38.6×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+3.6%
Mar '25
+10.6%
Jun '25
+13.3%
Sep '25
+14.3%
Dec '25
+14.3%
Mar '26
+9.7%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.2B, diluted EPS $4.27.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 STE STERIS plc64Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 11 Good · ● 3 Average · ● 2 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldBad
Risk models
Altman Z''Good
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAGood
Interest coverGood
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 67/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $3.2B | $3.4B | $3.7B | $3.9B | $4.3B |
| Operating income | $932M | $899M | $1.1B | $1.1B | $1.4B |
| Net income | $745M | $679M | $845M | $888M | $1.1B |
| Operating cash flow | $756M | $543M | $907M | $929M | $1.2B |
| Operating margin | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% |
| Free cash flow | $636M | $394M | $773M | $808M | $1.1B |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
10 bullish · 1 neutral · 5 bearish
Weekly
Bullish
8 bullish · 1 neutral · 3 bearish
Monthly
Bearish
2 bullish · 1 neutral · 5 bearish
Moving averages (daily)
| SMA 10 | 526.1 | Bullish |
| EMA 10 | 531.9 | Bullish |
| SMA 20 | 523.7 | Bullish |
| EMA 20 | 527.5 | Bullish |
| SMA 50 | 535.2 | Bullish |
| EMA 50 | 533.3 | Bullish |
| SMA 100 | 547.3 | Bullish |
| EMA 100 | 546.7 | Bullish |
| SMA 200 | 579.7 | Bearish |
| EMA 200 | 564.5 | Bearish |
Oscillators (daily)
| RSI (14) | 65.99 | Neutral |
| MACD (12, 26) | 2.46 | Bullish |
| Momentum (12) | 7.31 | Bullish |
| Stochastic %K (14) | 90.53 | Bearish |
| Williams %R (14) | -9.47 | Bearish |
| CCI (20) | 338.5 | Bearish |
Pivot points (classic, last session)
S3 539.2 | S2 545.9 | S1 553.1 | Pivot 559.8 | R1 567.1 | R2 573.8 | R3 581.0 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
IDXX SEC filings
4 Aug 2026
8-KSEC EDGAR
Results of operations
4 Aug 2026
10-QSEC EDGAR
Quarterly report
15 May 2026
8-KSEC EDGAR
Shareholder vote results
5 May 2026
8-KSEC EDGAR
Results of operations
5 May 2026
10-QSEC EDGAR
Quarterly report
27 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
26 Mar 2026
8-KSEC EDGAR
Director or officer change
20 Feb 2026
10-KSEC EDGAR
Annual report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.